NRSN
NeuroSense Therapeutics Ltd.
Biotechnology
Market Cap$20M
5Y Perf.-64.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NRSN vs ANVS
Revenue, margins, valuation, and 5-year total return — side by side.
ANVS
Annovis Bio, Inc.
Biotechnology
Market Cap$62M
5Y Perf.-87.1%
NRSN vs ANVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NRSN | ANVS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $20M | $62M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-9M | $-29M |
| Total Debt | $73K | $0.00 |
| Cash & Equiv. | $3M | $19.53B |
NRSN vs ANVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NRSN
ANVS
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| NeuroSense Therapeu… (NRSN) | 100 | 35.7 | -64.3% |
| Annovis Bio, Inc. (ANVS) | 100 | 12.9 | -87.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NRSN vs ANVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANVS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. NeuroSense Therapeutics Ltd. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NRSN
NeuroSense Therapeutics Ltd.
The Income Pick
NRSN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.27
- Lower volatility, beta 1.27, Low D/E 2.8%, current ratio 2.21x
- Beta 1.27, current ratio 2.21x
Best for: income & stability and sleep-well-at-night
ANVS
Annovis Bio, Inc.
The Growth Play
ANVS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 99.9%
- -76.3% 10Y total return vs NRSN's -78.3%
- 100.4% revenue growth vs NRSN's -2.8%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANVS | 100.4% revenue growth vs NRSN's -2.8% |
| Quality / Margins | ANVS | 0.0% margin vs NRSN's -6.8% |
| Stability / Safety | NRSN | Beta 1.27 vs ANVS's 2.16 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ANVS | +43.7% vs NRSN's -14.0% |
| Efficiency (ROA) | ANVS | -0.5% ROA vs NRSN's -5.1% |
NRSN vs ANVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANVSLAGGINGNRSN
NRSNNeuroSense Therapeuti…
1leads
ANVSAnnovis Bio, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs NRSNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ANVS1/1
Valuation MetricsMultiples, price ratios, and targets
ANVS2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANVS5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
NRSN4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ANVS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NRSN and ANVS operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NRSNNeuroSense Therap… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$9M | -$30M |
| Net IncomeAfter-tax profit | -$9M | -$29M |
| Free Cash FlowCash after capex | -$2,000 | -$853M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -95.2% | +16.7% |
ANVS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ANVS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | NRSNNeuroSense Therap… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| Market CapShares × price | $20M | $62M |
| Enterprise ValueMkt cap + debt − cash | $17M | -$19.5B |
| Trailing P/EPrice ÷ TTM EPS | -1.59x | -1.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.32x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
ANVS leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ANVS leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ANVS delivers a -0.7% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-29 for NRSN. On the Piotroski fundamental quality scale (0–9), NRSN scores 3/9 vs ANVS's 2/9, reflecting mixed financial health.
| Metric | NRSNNeuroSense Therap… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -28.8% | -0.7% |
| ROA (TTM)Return on assets | -5.1% | -0.5% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -8.6% | -0.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$3M | -$19.5B |
| Cash & Equiv.Liquid assets | $3M | $19.5B |
| Total DebtShort + long-term debt | $73,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -97.39x | — |
ANVS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
NRSN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NRSN five years ago would be worth $2,171 today (with dividends reinvested), compared to $967 for ANVS. Over the past 12 months, ANVS leads with a +43.7% total return vs NRSN's -14.0%. The 3-year compound annual growth rate (CAGR) favors NRSN at -20.3% vs ANVS's -46.5% — a key indicator of consistent wealth creation.
| Metric | NRSNNeuroSense Therap… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +12.4% | -37.8% |
| 1-Year ReturnPast 12 months | -14.0% | +43.7% |
| 3-Year ReturnCumulative with dividends | -49.3% | -84.7% |
| 5-Year ReturnCumulative with dividends | -78.3% | -90.3% |
| 10-Year ReturnCumulative with dividends | -78.3% | -76.3% |
| CAGR (3Y)Annualised 3-year return | -20.3% | -46.5% |
NRSN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NRSN and ANVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
NRSN is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than ANVS's 2.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANVS currently trades 41.3% from its 52-week high vs NRSN's 33.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NRSNNeuroSense Therap… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 2.16x |
| 52-Week HighHighest price in past year | $2.60 | $5.50 |
| 52-Week LowLowest price in past year | $0.63 | $1.44 |
| % of 52W HighCurrent price vs 52-week peak | +33.7% | +41.3% |
| RSI (14)Momentum oscillator 0–100 | 63.3 | 63.5 |
| Avg Volume (50D)Average daily shares traded | 157K | 889K |
Evenly matched — NRSN and ANVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NRSNNeuroSense Therap… | ANVSAnnovis Bio, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ANVS leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). NRSN leads in 1 (Total Returns). 1 tied.
Best OverallAnnovis Bio, Inc. (ANVS)Leads 3 of 6 categories
Loading custom metrics...
NRSN vs ANVS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NRSN or ANVS?
Over the past 5 years, NeuroSense Therapeutics Ltd.
(NRSN) delivered a total return of -78. 3%, compared to -90. 3% for Annovis Bio, Inc. (ANVS). Over 10 years, the gap is even starker: ANVS returned -76. 3% versus NRSN's -78. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NRSN or ANVS?
By beta (market sensitivity over 5 years), NeuroSense Therapeutics Ltd.
(NRSN) is the lower-risk stock at 1. 27β versus Annovis Bio, Inc. 's 2. 16β — meaning ANVS is approximately 71% more volatile than NRSN relative to the S&P 500.
03Which is growing faster — NRSN or ANVS?
On earnings-per-share growth, the picture is similar: Annovis Bio, Inc.
grew EPS 99. 9% year-over-year, compared to 33. 7% for NeuroSense Therapeutics Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NRSN or ANVS?
NeuroSense Therapeutics Ltd.
(NRSN) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Annovis Bio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRSN leads at 0. 0% versus 0. 0% for ANVS. At the gross margin level — before operating expenses — NRSN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NRSN or ANVS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NRSN or ANVS better for a retirement portfolio?
For long-horizon retirement investors, NeuroSense Therapeutics Ltd.
(NRSN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). Annovis Bio, Inc. (ANVS) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRSN: -78. 3%, ANVS: -76. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NRSN and ANVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.